| 研究No. |
執筆者/論文タイトル/掲載誌 |
TORG1018
related article |
Taniguchi Y, Okamoto H, Shimokawa T, et al.: Concurrent chemoradiotherapy with cisplatin+S-1 versus cisplatin+other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data. BMC Pulmonary Medicine 22: 31-42, 2022 |
| TORG1630 |
Taniguchi Y, Shimokawa T, Takiguchi Y et al.: A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naive non-small-cell lung cancer: TORG1630. Clinical Cancer Research 22: 4402-4409, 2022
doi.org/10.1158/1078-0432.ccr-22-1687 |
| TORG1936 |
Ikeda S, Kato T, Kenmotsu H, et al.: Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study. The Oncologist 27: 720-e702, 2022
doi: 10.1093/oncolo/oyac118 |
TORG1936
related article |
Ikeda S, Misumi T, Kato T, et al.: Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases Really Mild and Easily Manageable? CHEST 162: E65-E66, 2022. doi: 10.1016/j.chest.2022.02.057 |
| TORG2040 |
Fukui T, Sasaki J, Igawa S, et al.: Rationale and protocol design of a phase II study of frst-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). BMC Cancer 22: 1314, 2022
https://doi.org/10.1186/s12885-022-10409-6 |
| 研究No. |
執筆者/論文タイトル/掲載誌 |
| TORG1018 |
Shimokawa T, Yamada K, Tanaka H, et al.: Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer. Cancer Medicine 10: 626-633, 2021 |
| TORG1632 |
Noro R, Igawa S, Bessho A, et al.: A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. Lung Cancer 161: 49-54, 2021 |
TORG1936
related article |
Ikeda S, Kato T, Kenmotsu H, et al.Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. European Journal of Cancer 151: 249-251, 2021 (Letter to the Editor) doi.org/10.1016/j.ejca.2021.03.050 |
| 研究No. |
執筆者/論文タイトル/掲載誌 |
| TORG0503 |
Kubota K, Kunitoh H, Seto T, et al.: Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503. Lung Cancer 141: 32-36, 2020 |
TORG0808
TORG0913 |
Nakahara Y, Shimokawa T, Misumi Y, et al.: Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913. Investigational New Drugs (published online 15 Aug 2020) doi: 10.1007/s10637-020-00985-4 |
| TORG1320 |
Otani S, Sasaki J, Nakahara Y, et al.: Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320). Investigational New Drugs (published online 07 Nov 2020) doi: 10.1007/s10637-020-01031-z |
| TORG1322 |
Zenke Y, Niho S, Umemura S, et al.: Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322. Lung Cancer 146 (8): 182-188, 2020. doi:10.1016/j.lungcan.2020.05.005 |
| TORG1323 |
Kozuki T, Nogami N, Hataji O, et al.: Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational Lung Cancer Research 9 (3) : 459-470, 2020. doi: 10.21037/tlcr.2020.03.29 |
| TORG1425 |
Miyamoto S, Azuma K, Ishii H, et al.: Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: A multicenter Phase 2 trial. JAMA Oncology 6 (7): e201250. doi: 10.1001/jamaoncol.2020.1250 |
| TORG1834 |
Miura S, Yamanaka T, Kato T, et al.: Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clinical Lung Cancer 21 (6): e592-e596. doi: 10.1016/j.cllc.2020.05.011 |
| TORG1835 |
Ikeda S, Ogura T, Kato T, et al.: Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis. Therapeutic Advances in Medical Oncology 12: 1-6, 2020. doi: 10.1177/1758835920923431 |
| TORG1936 |
Ikeda S, Kato T, Kenmotsu H, et al. A phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias. Journal of Thoracic Oncology 15: 1935-1942, 2020. doi: 10.1016/j.jtho.2020.08.018 |
| Ikeda S, Kato T, Kenmotsu H, et al.: A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study. Therapeutic Advances in Medical Oncology 12: 1-6, 2020. doi: 10.1177/1758835920922022 |
| 研究No. |
執筆者/論文タイトル/掲載誌 |
| TORG0809 |
Niho S, Ikeda N, Michimae H, et al.Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809. American Journal of Clinical Oncology 41: 1113-1117, 2018. doi: 10.1097/COC.0000000000000438 |
| TORG1016 |
Ikeda S, Kato T, Ogura T, et al.: Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. BMC Cancer 18: 241, 2018 |
| 研究No. |
執筆者/論文タイトル/掲載誌 |
| TORG0910 |
Yamada K, Saito H, Kondo T, et al.: Multicenter phase II study of nedaplatin and irinotecan for patients with squamous cell carcinoma of the lung: Thoracic Oncology Research Group 0910. Anticancer Research 35 (12): 6705-6711, 2015 |
| TORG0911 |
Yamada K, Aono H, Hosomi Y, et al.: A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non?small cell lung cancer with EGFR mutations: Thoracic Oncology Research Group 0911. European Journal of Cancer 51 (14) : 1904-1910, 2015 |
| TORG1014 |
Takagi Y, Hosomi Y, Oshita F, et al.: Feasibility study of docetaxel plus bevacizumab therapy for elderly patients with non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. BMC Cancer 15: 740, 2015 |
